Teva Pharmaceutical Industries Ltd

Latest Results (09.09.2025):

Teva Pharmaceutical Industries Ltd reported its Q2 2025 financial results, marking the company's 10th consecutive quarter of year-over-year revenue growth. Revenues reached $4.2 billion, with increased outlooks for key innovative products and earnings per share (EPS). Teva also reaffirmed its overall financial outlook while advancing its Pivot to Growth strategy towards a 30% operating profit margin by 2027.

Revenue Performance

In Q2 2025, Teva achieved revenues of $4.2 billion, representing a 1% increase in local currency terms compared to Q2 2024. The United States segment grew by 2%, Europe by 3%, while International Markets saw a 4% decline, excluding Japan BV revenues.

Innovative Portfolio Growth

Teva's key innovative products drove significant growth, with AUSTEDO® revenues up 19% to $498 million, AJOVY® increasing by 31% to $155 million, and UZEDY® soaring 120% to $54 million in Q2 2025. The company has raised the 2025 revenue outlook for these products, expecting AUSTEDO® to reach $2,000–$2,050 million, AJOVY® $630–$640 million, and UZEDY® $190–$200 million.

EPS and Profitability

Teva reported a GAAP diluted EPS of $0.24 and a non-GAAP diluted EPS of $0.66, marking a 9% year-over-year increase. The company remains on track to achieve a 30% operating profit margin by 2027 as part of its Pivot to Growth strategy.

Cash Flow and Financial Strength

The company generated $227 million from operating activities and $476 million in free cash flow for Q2 2025, reflecting a 47% year-over-year increase. Teva reaffirmed its 2025 financial outlook, including revenues of $16.8–$17.2 billion and non-GAAP diluted EPS of $2.50–$2.65.

Generics and Biosimilars Performance

Teva's generics business remained stable with global generics revenues down 2% in local currency. However, biosimilars showed strong performance, with growth from existing and newly launched products. The company expects to double biosimilar revenues from 2024 to 2027, with two new launches planned for the second half of 2025.

Transformation Programs Progress

Teva continues to advance its Transformation programs, targeting approximately $700 million in net savings by 2027. In 2025, the company expects to achieve around $70 million in net savings, contributing to the overall efficiency and profitability goals.